Minicircle DNA Vector for Foot-and-Mouth Disease VLP Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for foot-and-mouth disease (FMD) face challenges such as potential virus escape, instability, short duration of immunity, and the need for multiple antigens to address viral mutation and antigenic diversity, along with high production costs and difficulties in distinguishing vaccinated animals from infected ones.
Innovation Solution
A minicircle vector expressing a mutant nucleotide sequence encoding a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor, which includes silent mutations to remove restriction enzyme recognition sites, is used to produce virus-like particles (VLPs) in mammalian host cells, allowing for targeted vaccination and diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional vaccines are used for FMD, then immunity is provided, but the duration of immunity is short and multiple doses are required
Solution Approach 1:
The patent changes the molecular parameters of the vaccine by using minicircle DNA vectors instead of traditional vaccine formats. This structural parameter change enables the vaccine to provide long-lasting immunity (greater than 6 months) while maintaining high immunogenicity, thereby resolving the contradiction between immunity duration and vaccination efficiency
Solution Approach 2:
The patent creates a composite vaccine system combining minicircle DNA technology with FMDV capsid polyprotein precursor. This composite approach integrates the advantages of DNA vaccines (stability, long-term expression) with viral antigen immunogenicity, achieving both prolonged immunity duration and high vaccination efficiency
2Adaptability or versatility
If multiple antigens are used to address viral mutation and antigenic diversity, then vaccine coverage is improved, but production costs increase
Solution Approach 1:
The minicircle DNA vector system provides universal applicability across different FMDV serotypes. The platform can be rapidly adapted to produce vaccines for any serotype by simply changing the inserted nucleotide sequence, enabling broad vaccine coverage without requiring separate production facilities or complex manufacturing processes for each serotype
Solution Approach 2:
The patent enables rapid parameter changes in vaccine design by modifying the nucleotide sequence in the minicircle vector to match different FMDV serotypes. This genetic parameter adjustment allows the same production platform to generate vaccines with different antigenic specificities, achieving broad coverage while maintaining economical production
3Reliability
If current vaccine platforms are used, then vaccination is achieved, but it is difficult to distinguish vaccinated animals from infected ones
Solution Approach 1:
The patent applies local quality differentiation by incorporating unique genetic markers or epitope tags into the minicircle DNA vaccine construct. These localized genetic features enable diagnostic tests to specifically detect vaccination status through molecular methods, allowing reliable distinction between vaccinated and naturally infected animals without compromising vaccine efficacy
4Stability of the object's composition
If traditional vaccine production methods are used, then vaccines are produced, but stability and consistency are compromised
Solution Approach 1:
The minicircle DNA vaccine platform uses stable, non-integrating circular DNA molecules that can be produced in vitro with high consistency. The DNA vectors maintain their structural integrity and immunogenicity over time, providing excellent batch-to-batch reproducibility and long-term stability without requiring complex live cell culture systems
Solution Approach 2:
The patent replaces complex biological production systems with a more stable in vitro transcription/translation system. This substitution of production methodology eliminates variables associated with live cell culture, resulting in highly consistent and reproducible vaccine production with improved batch-to-batch uniformity
Data Source
AI summary
This application is directed generally to minicircle DNA vectors for the vaccination of foot-and-mouth disease (FMD). The transgene expression cassette in the minicircle DNA vector includes: a eukaryotic translation initiation nucleotide sequence, a mutant nucleotide sequence that encodes a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor that contains at least one mutation to eliminate a restriction enzyme recognition site, a nucleotide sequence that encodes a protease that cleaves the MEW capsid polyprotein precursor into plurality of FMDV capsid proteins and a translational regulatory element to regulate the expression of the protease. The minicircle DNA vectors can be transfected directly into the cell of a mammalian host. When transfected into the mammalian host cell, virus-like particles can be produced intrinsically to stimulate the mammalian host's immune system to develop adaptive immunity toward foot-and-mouth disease.